<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094182</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-1146</org_study_id>
    <nct_id>NCT03094182</nct_id>
  </id_info>
  <brief_title>Efficacy of Intravenous Iron Therapy in Maintaining Hemoglobin Concentration on Patients Undergoing Bimaxillary Orthognathic Surgery</brief_title>
  <official_title>Efficacy of Intravenous Iron Therapy in Maintaining Hemoglobin Concentration on Patients Undergoing Bimaxillary Orthognathic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of Intravenous iron isomaltoside on
      maintaining hemoglobin concentration in patients undergoing bimaxillary orthognathic surgery.
      Fifty-eight patients, aged 19 to 40 years, scheduled for Bimaxillary orthognathic surgery
      will be divided into monofer (n=29) and control (n=29) groups. Randomly selected patients of
      the ulinastatin group are given intravenous iron isomaltoside. In contrast, patients in the
      control group receive an equivalent volume of normal saline as a placebo. The primary
      endpoints are postoperative hemoglobin concentration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bimaxillary orthognathic surgery is widely used to correct dentofacial anomaly and
      bimaxillary prognathism. However, the complicated vascularity of the surgical site and
      limited visual field can lead to unexpected bleeding. Intravenous iron isomaltoside 1000
      (monofer速) significantly increased the hemoglobin level and prevented anemia 4 weeks after
      cardiac surgery. The aim of this study is to evaluate the effect of Intravenous iron
      isomaltoside on maintaining hemoglobin concentration in patients undergoing bimaxillary
      orthognathic surgery. Fifty-eight patients, aged 19 to 40 years, scheduled for Bimaxillary
      orthognathic surgery will be divided into monofer (n=29) and control (n=29) groups. Randomly
      selected patients of the ulinastatin group are given intravenous iron isomaltoside. In
      contrast, patients in the control group receive an equivalent volume of normal saline as a
      placebo. The primary endpoints are postoperative hemoglobin concentration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative hemoglobin level</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>Postoperative hemoglobin concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative hemoglobin level</measure>
    <time_frame>2 weeks after surgery</time_frame>
    <description>Postoperative hemoglobin concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative hemoglobin level</measure>
    <time_frame>4 weeks after surgery</time_frame>
    <description>Postoperative hemoglobin concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hematogenous function</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>the hematogenous function measured by serum iron, ferritin, transferrin saturation, and total iron binding capacity, reticulocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematogenous function</measure>
    <time_frame>2 weeks after surgery</time_frame>
    <description>the hematogenous function measured by serum iron, ferritin, transferrin saturation, and total iron binding capacity, reticulocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematogenous function</measure>
    <time_frame>4 weeks after surgery</time_frame>
    <description>the hematogenous function measured by serum iron, ferritin, transferrin saturation, and total iron binding capacity, reticulocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>the quality of life measured by LASA(Linear Analogue Self Assessment) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>2 weeks after surgery</time_frame>
    <description>the quality of life measured by LASA(Linear Analogue Self Assessment) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>4 weeks after surgery</time_frame>
    <description>the quality of life measured by LASA(Linear Analogue Self Assessment) questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Facial Asymmetry</condition>
  <arm_group>
    <arm_group_label>ulinastatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the ulinastatin group are given Intravenous iron isomaltoside during operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the control group receive the same volume of normal saline during operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Isomaltoside 1000</intervention_name>
    <description>Randomly selected patients of the monofer group are given 1000mg of iron isomaltoside, which are mixed in 100ml normal saline, intravenous after induction for 30 minutes.</description>
    <arm_group_label>ulinastatin group</arm_group_label>
    <other_name>monofer速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who are scheduled to undergo bimaxillary orthognathic surgery

          -  American Society of Anesthesiologists (ASA) physical status I-II

        Exclusion Criteria:

          -  hematologic disease

          -  renal-related anemia

          -  hepatitis

          -  pregnancy

          -  hypersensitivity to iron

          -  severe atopic disease

          -  allergic to drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bon-Nyeo Koo, M.D., Ph.D.</last_name>
    <phone>82-2-2227-3919</phone>
    <email>koobn@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bon-Nyeo Koo, M.D., Ph.D.</last_name>
      <phone>02-2227-3835</phone>
      <email>koobn@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer速) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang. 2015 Oct;109(3):257-66. doi: 10.1111/vox.12278. Epub 2015 Apr 20.</citation>
    <PMID>25900643</PMID>
  </reference>
  <reference>
    <citation>Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer(速)) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016 Mar 10;9:53-64. doi: 10.2147/IJNRD.S89704. eCollection 2016. Review.</citation>
    <PMID>27022297</PMID>
  </reference>
  <reference>
    <citation>Oh AY, Seo KS, Lee GE, Kim HJ. Effect of preoperative autologous blood donation on patients undergoing bimaxillary orthognathic surgery: a retrospective analysis. Int J Oral Maxillofac Surg. 2016 Apr;45(4):486-9. doi: 10.1016/j.ijom.2015.11.008. Epub 2015 Dec 8.</citation>
    <PMID>26678802</PMID>
  </reference>
  <reference>
    <citation>Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013 Aug 15;347:f4822. doi: 10.1136/bmj.f4822. Review.</citation>
    <PMID>23950195</PMID>
  </reference>
  <reference>
    <citation>Choi BK, Yang EJ, Oh KS, Lo LJ. Assessment of blood loss and need for transfusion during bimaxillary surgery with or without maxillary setback. J Oral Maxillofac Surg. 2013 Feb;71(2):358-65. doi: 10.1016/j.joms.2012.04.012. Epub 2012 Jun 16.</citation>
    <PMID>22705218</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facial Asymmetry</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

